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The Urabe AM9 strain of mumps vaccine live is known for its genetic instability and some vaccines derived from this strain
were withdrawn from the market due to an excessive number of vaccine-associated parotitis and meningitis cases. To
identify the molecular basis of this instability, we determined complete nucleotide sequences of several stocks of the Urabe
strain used for vaccine production by different manufacturers and of two clinical isolates from cases of vaccine-associated
meningitis. In contrast to previously published studies relating the Lys335 3 Glu mutation in the viral HN gene with
neurovirulence of mumps virus, we could not confirm any association of this mutation with the safety of mumps vaccine. Each
of the three vaccine stocks studied had its own characteristic profile of mutations that was identified by cDNA sequencing
and quantitated by mutant analysis by PCR and restriction enzyme cleavage. Determination of the mutational profile of
mumps vaccine lots could allow vaccine manufacturers to characterize seed viruses and monitor the consistency of vaccine
production to prevent emergence of virulent revertants.
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Mumps virus is a member of the Rubulavirus genus of
the Paramyxoviridae family. It has a single-stranded neg-
ative-sense RNA genome of 15,384 nucleotides that en-
codes seven proteins: nucleocapsid (NP), phosphopro-
tein (P), matrix (M), fusion (F), small hydrophobic (SH),
hemagglutinin-neuraminidase (HN), and RNA polymer-
ase (L). Due to the inherent genetic instability of RNA
viruses, mumps virus contains a heterogeneous mixture
of genomic RNA molecules with slightly different nucle-
otide sequences (quasispecies) (Afzal et al., 1992, 1993;
Boriskin et al., 1993; Brown et al., 1996; Yates et al., 1996).
Virus growth both in vitro and in vivo results in selection
of different subpopulations, depending on growth condi-
tions (Boriskin et al., 1992, 1993; Turner et al., 1991). This
affects important properties of the virus such as viru-
lence. This genetic plasticity permitted selection of at-
tenuated strains of mumps virus by serially passaging it
in chicken embryos and cell cultures of quail or chicken
fibroblasts (Buynak and Hilleman, 1966; Hilleman, 1966;
Stokes, 1967). Following the introduction and success of
the Jeryl Lynn vaccine strain in the United States (Hille-
man, 1966), a number of other strains were developed for
vaccine manufacture internationally. Some of the strains
have a mixed record of efficacy and safety because of
the propensity of attenuated viruses to change, often
with partial regaining of virulent properties (Levenbuk et
al., 1979; Sugiura and Yamada, 1991). The Urabe AM9
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234strain, which was developed in Japan in the late 1960s,
was used by a number of Japanese and European man-
ufacturers for vaccine production. Postmarketing surveil-
lance in Japan, Canada, and the United Kingdom re-
vealed an unacceptably high rate of vaccine-associated
meningitis (Autret et al., 1996; Black et al., 1997; Dourado
et al., 2000; McDonald et al., 1989; Miller et al., 1993;
Nalin, 1989; Rebiere and Galy-Eyraud, 1995; Ueda et al.,
1995), parotitis (Brunell et al., 1972), and orchitis cases
(Kuczyk et al., 1994), which led to a withdrawal of the
product from the market in these countries (Colville et al.,
1994; Sawada et al., 1993). However, other manufactur-
ers still continue to use this strain for vaccine production
without an excess number of adverse reactions. Al-
though a passive adverse event reporting system can be
inaccurate, still this suggests that the Urabe AM9 strain
is prone to genetic variability, which may affect its safety
profile.
It is clear that there are gaps in understanding the
pathogenicity of the virus, hindering our ability to develop
adequate laboratory tests for mumps vaccine safety (Mi-
nor, 1997). Knowledge of the molecular nature of atten-
uation and reversion to neurovirulence of oral poliovirus
vaccine (OPV) allowed us to develop a molecular method
for consistency monitoring of vaccine production by di-
rectly measuring contents of neurovirulent revertants in
batches of OPV (Chumakov, 1999; Chumakov et al., 1991).
Elucidation of the molecular mechanism of attenuation of
other live vaccines, and of pathways of their reversion to
virulence, could help in development of similar molecular
quality control methods. In the case of mumps vaccine










































235GENETIC VARIABILITY OF MUMPS VACCINE URABE AM9 STRAINtional importance since at present there is no validated
in vivo or in vitro test for neurovirulence of the virus that
could be routinely used for quality control of this vaccine
(Afzal et al., 1999; Maximova et al., 1996; Rubin et al.,
1998, 1999). In addition to safety concerns, variability and
plasticity of mumps virus genome may also have impli-
cations for vaccine efficacy, since some attenuated
strains of the virus were found to be insufficiently immu-
nogenic (Chamot et al., 1998; Gassner et al., 1995).
The issue of instability of attenuation of the Urabe AM9
strain was previously addressed in a number of studies.
Partial analysis of cDNA sequences of several isolates
from vaccine-associated meningitis and parotitis cases
was performed and led to identification of a sequence
heterogeneity in the viral HN gene (Brown et al., 1996). It
was suggested that the Lys335 3 Glu mutation in the HN
ene is responsible for attenuation of the wild-type virus,
nd reversion at this site partially restores virulence of
he vaccine (Brown and Wright, 1998). The vaccine pro-
uced by different manufacturers was found to contain
ariable amounts of both Lys and Glu at this site, and it
as hypothesized that the safety of the vaccine depends
n the relative abundance of the variants. However, the
onclusions were based on only partial sequencing of
he viral genome, which was done after cDNA cloning.
herefore, it is possible that some of the mutations re-
ponsible for attenuation/reversion may have been
issed. In this communication we report our studies of
he mutational composition of different mumps virus
tocks made from the Urabe strain in attempts to develop
urrogate molecular methods for consistency control of
his vaccine.
RESULTS
uantification of 7616-G 3 A
To study the Glu335 3 Lys mutation in the HN gene
(7616-G 3 A at the nucleotide level), we have used a
MAPREC, mutant analysis by PCR and restriction en-
zyme cleavage, to directly measure contents of both
7616-G and 7616-A in virus samples (Chuma Kov et al.,
1991). Unlike the similar test described in Brown et al.
(1996), which detected only 7616-A by digestion with
MseI restriction endonuclease (recognizing TTAA), we
also digested the PCR-amplified DNA with 7616-G-spe-
cific HinfI (recognizing GANTC). As a result we could
directly measure both nucleotides and confirmed that the
balance of their contents was close to 100%. When we
tested vaccine batches produced by SmithKline
Beecham (Lot Nos. MP51, MP52, and MP53) that were
withdrawn from the market, we found that they contained
88.9 6 1.9% of the “wild-type” 7616-A and only 9.2 6 1.3%
f “attenuated” 7616-G (Fig. 1). On the other hand, vaccine
hat is still produced by Chiron SpA (Lot Nos. PS22, PS23,
S24, PS25, and PS27) and was not associated with an
xcessive number of adverse reactions contained no ldetectable “attenuated” base, but had 100% of the wild-
type base. This result is not consistent with the interpre-
tation of the previously published studies that Lys335 is
associated with higher virulence of the Urabe strain.
Interestingly, the Jeryl Lynn strain, which is highly atten-
uated and has an excellent safety record, also contains
100% of the wild-type 7616-A, as do all other mumps virus
strains that we sequenced (G. Amexis et al., to be pub-
ished).
equences of commercial Urabe AM9 substrains and
f isolates from vaccine-associated meningitis cases
We determined the complete nucleotide sequences of
he Urabe substrains made by Biken, SB, and Chiron SpA
hat appear to have different safety records. We also
equenced two isolates from cases of vaccine-associ-
ted meningitis hoping to match any mutations identical
o those that may be present in the vaccine batches.
ucleotide sequences of all three vaccine sources dif-
ered from the published sequence at nucleotide 7409 (A
n the published sequence but G in all stocks that we
tudied). This mutation may have been a result of a
loning step used to derive the previously published
equence. There were also a few nucleotide heteroge-
eities that distinguished the three virus stocks from one
nother. Some of them matched the mutations found in
linical isolates. All mutations identified in vaccine
tocks and clinical isolates are listed in Table 1. How-
ver, there was no mutation that was present in both
linical isolates, suggesting that their increased viru-
FIG. 1. MAPREC analysis of nucleotide 7616 (coding for amino acid
335 in HN protein) in mumps vaccine batches produced by SB and
Chiron SpA. HinfI cuts DNA with 7616-G (Glu335), and MseI cuts DNA
with 7616-A (Lys335). Digested materials were loaded on duplicate
lanes. Upper band represents undigested DNA molecules, and this
band is poorly resolved from another minor unidentified PCR product
moving slightly ahead of it. Lower band represents DNA molecules cut
with respective restriction enzymes, and their quantities reflect the
contents of 7616-G and 7616-A.ence was a result of different reversion pathways.
236 AMEXIS, FINESCHI, AND CHUMAKOVMutational profiles of different Urabe vaccine
products
Vaccines produced by Chiron SpA and SB contained a
number of sites where two nucleotides could be de-
tected. Six such heterogeneous sites were found in SB
batches (7616-G1A, 8005-C1A, 8015-G1A, 9972-T1C,
10529-C1T, and 11692-G1T) and two in Chiron SpA
batches (8015-G1A and 9972-T1C), leading to a change
at the amino acid level as well. It is noteworthy that a
mutation at one of the heterogeneous sites (9972) was
also found in one of the clinical isolates. It can be
assumed that biological properties of the vaccines de-
pend on the composition of the respective quasispecies
comprising them. To determine the quantitative muta-
tional profiles of the viral stocks, we designed MAPREC
assays for these mutations and tested the commercial
vaccine preparations available to us. Figures 2A and 2B
show nucleotide heterogeneity at position 8005 ob-
served in vaccine batches from SB, but not in batches
from Chiron SpA. 8005-A coding for Lys464 in HN protein
was also found in one of the clinical isolates. In contrast,
Chiron SpA batches appeared homogeneous at this nu-
cleotide and contained only 8005-C (Asn464). Figure 3
shows the difference between batches of vaccines from
SB and Chiron SpA at nucleotide 10,529. Batches pro-
duced by SB were heterogeneous and contained both
10529-C and 10529-T, while the Chiron SpA product con-
tained only 10529-T. Table 2 summarizes the results of
quantitative mutational analysis of both products and
shows that they have distinguishing mutational profiles.
Passaging of Urabe stocks in CEF cultures
Virus growth during vaccine production can result in
T
Nucleotide Differences and Heterogeneities in Mumps V




1,880 NP C C C
6,385 HN C C C
7,409 HN A G G
7,573 HN T T T
7,616 HN A Lys A Lys A
8,005 HN C Asn C Asn C
8,015 HN G Glu G Glu A/G
9,972 L T Phe T Phe C/T
10,529 L C Pro C Pro C
11,692 L G Leu G Leu G
14,049 L C C C
15,328 UTR G G G
Note. Amino acids are presented only for missense mutations.
a Urabe AM9 sequence (GenBank Accession No. AB000387).accumulation of some mutations and affect the final 8mutational profile of the product. Therefore, to assess the
genetic stability of the vaccine, we performed serial pas-
saging of Chiron SpA mumps virus stock in chicken
embryo fibroblast (CEF) cells and determined contents of
mutations at heterogeneous sites by MAPREC. There
was no change at nucleotide 8005 at which the Chiron
SpA vaccine was homogeneous but the SB product con-
tained both A and C (Fig. 3C). The same result was
obtained for nucleotide 10,529 (data not shown). Addi-
tional passaging in CEF cells resulted in a disappear-
ance of sequence heterogeneity at nucleotide 9972,
which was present in both SB and Chiron SpA vaccines
(Fig. 4C). Vaccine batches produced by both companies
contained 26–37% 9972-T, while after additional passag-
ing in CEF cells no 9972-T could be detected, suggesting
s Made from the Urabe Strain by Three Manufacturers








ys A/G Lys/Glu A Lys A Lys
sn A/C Lys/Asn C Asn A Lys
ys/Glu A/G Lys/Glu G Glu G Glu
er/Phe C/T Ser/Phe C Ser T Phe
ro C/T Pro/Leu C Pro T Leu
eu G/T Leu/Phe G Leu T Phe
C C T
G A G
FIG. 2. MAPREC analysis of nucleotide 8005 in mumps vaccine
batches produced by SB (A) and Chiron SpA (B) and in virus stock
produced by growing a Chiron SpA vaccine lot in CEF cells for three











































237GENETIC VARIABILITY OF MUMPS VACCINE URABE AM9 STRAINthat the mutant 9972-C-containing virus has a selective
advantage during virus growth in these cells. Interest-
ingly, 9972-C, coding for Ser512 in the L protein, could also
e found in one of the clinical isolates.
DISCUSSION
Some mumps virus strains used for manufacture of
ive vaccines are known for their genetic instability, be-
ieved to cause increased neurovirulence and an exces-
ive number of parotitis and aseptic meningitis cases in
accine recipients. A number of factors, including those
etermined by a host, affect the level of pathogenicity of
ttenuated vaccine strains. However, different safety
ecords of mumps vaccines produced from different
trains strongly suggest that genetic properties of an
ttenuated strain play a major role. For instance, while
he Jeryl Lynn strain was never found to cause excessive
dverse reactions, there are a number of reports from
FIG. 3. MAPREC analysis of nucleotide 10,529 in mumps vaccine
batches produced by SB (A) and Chiron SpA (B). BspMI cuts 10529-T,
and the lower band is indicative of the amount of this base. There is no
10529-C-specific restriction enzyme, so its content is assessed by the
quantity of undigested DNA (upper band).
TABLE 2
MAPREC Quantification of Mutants in Mumps Vaccines








7616-A MseI 96 88.9 7,581–7,668
7616-G HinfI 0 9.2
8005-A NsiI 2 50 7,963–8,052
8005-C HincII 90 45
9972-Ca n/a n/a n/a 9,900–10,010
9972-T BsmI 26 37
10529-T BspMI 93 27 10,490–10,560
10529-Cb n/a n/a n/a
a No 9972-C-specific enzyme is available.
b No 10529-C-specific enzyme is available.ifferent countries that the Urabe strain can cause an
xtremely high number of postvaccination meningitis
ases and other complications (Autret et al., 1996; Black
t al., 1997; Brunell et al., 1972; Dourado et al., 2000;
uczyk et al., 1994; McDonald et al., 1989; Miller et al.,
993; Nalin, 1989; Rebiere and Galy-Eyraud, 1995; Ueda
t al., 1995), which led to a withdrawal of some Urabe
M9-based vaccines from the market. Further evidence
hat the residual level of pathogenicity is controlled by
iral determinants comes from observations of genetic
nstability of some attenuated mumps virus strains. Lev-
nbuk et al. (1979) found that batches of the attenuated
3 strain with higher levels of neurovirulence in monkeys
ere also linked to an excessive incidence of postvac-
ination meningitis. Similar genetic instability is probably
property of the Urabe strain since vaccines made by
ifferent manufacturers have different safety records.
herefore studies aimed at understanding the underlying
enetic differences were initiated by several laboratories
few years ago.
Since direct laboratory methods for evaluation of neu-
opathogenicity of live mumps vaccine are not yet vali-
ated (Rubin et al., 1999), it is important to seek addi-
tional surrogate methods for evaluation of the genetic
stability of the virus. In this work we tried to create a
surrogate test for mumps vaccine prepared from the
Urabe strain based on a molecular consistency ap-
proach similar to the one that we used for quality control
of OPV (Chumakov, 1999; WHO, 1999). Two sources of
information can be used to identify appropriate sentinel
mutations. The first source is the mutations occurring in
attenuated strains isolated from cases of vaccine-asso-
FIG. 4. MAPREC analysis of nucleotide 9972 in mumps vaccine
batches produced by SB (A) and Chiron SpA (B) and in virus stock
produced by growing a Chiron SpA vaccine lot in CEF cells for three
additional passages (C). BsmI cuts 9972-T, and the lower band is
indicative of the amount of this base. There is no 9972-C-specific
restriction enzyme, so its content is assessed by the quantity of undi-



































































238 AMEXIS, FINESCHI, AND CHUMAKOVmutations that accumulate in the viral genome upon
growth under conditions of vaccine production. It is im-
portant to stress that both approaches can identify not
only mutations that are the true markers of pathogenicity,
but also incidental neutral mutations. While it is certainly
preferable to be able to accomplish the former goal, it
may not be possible without resorting to reverse genet-
ics, which is not well developed for this virus. In addition,
pathogenicity is a complex phenomenon that is likely to
be determined by multiple factors, making it hard and in
some cases impossible to identify a single mutation as
being the key to this property. However, failure to identify
the key molecular markers of pathogenicity does not
mean that a sensible surrogate method for monitoring of
genetic stability cannot be developed. We call this the
molecular consistency approach, which is based on trac-
ing of any shifts in mutational profiles of attenuated virus
during vaccine production. This approach has shown its
utility in our previous studies of OPV (Rezapkin et al.,
1994, 1995, 1999; Taffs et al., 1995).
Previous studies by Brown et al. (1996) pointed at a
Glu335 3 Lys mutation in the viral HN gene (nucleotide
7616 of the antigenome) as the one that was associated
with increased neurovirulence. Therefore it was logical
to start the search for appropriate sentinels from this
mutation. To our surprise we found that some vaccine
stocks not linked to excessive adverse reactions con-
tained 100% of the wild-type nucleotide (7616-A or Lys335)
at this site. On the other hand, vaccine that was with-
drawn from the market contained roughly 90% of the
wild-type 7616-A and only about 10% of the “attenuated”
7616-G. The stocks produced at Biken, the company that
was first to produce mumps vaccine from the Urabe
strain, are presumably closest to the original vaccine
strain and also contained 100% of 7616-A, as did both
clinical isolates from vaccine-related meningitis cases.
Therefore the only stock that contained a low but mea-
surable amount of 7616-G was the one with a higher level
of vaccine-associated meningitis, which, if anything, sug-
gests that 7616-G may be the culprit rather than an
attenuating nucleotide. Recently published findings
(Wright et al., 2000) showing that mumps virus strains
ith Lys335 are temperature sensitive and have a small-
laque phenotype are also in line with these doubts. The
ole of the 7616-A mutation in the pathogenicity of
umps virus was questioned by others as well (Afzal et
l., 1998; Mori et al., 1997). Additional evidence against
he role of 7616-A in neurovirulence comes from the
equencing of several substrains of Jeryl Lynn vaccine
G. Amexis, manuscript in preparation), which was never
ausally associated with severe adverse reactions. How-
ver, Jeryl Lynn differs from Urabe at more than 900
ucleotides, so its safety is likely to be determined by a
umber of other genetic loci.
The reason for the discrepancy between our conclu-
ions and the conclusions reached by previous investi- pators who described the mutation (Brown et al., 1996;
rown and Wright, 1998) may be due in part to the
ethod of quantification. We always directly quantified
oth “mutant” and “vaccine” bases by using different
estriction enzymes to ensure that the sum of both mu-
ations is close to 100%. In contrast, in the previously
ublished study only digestion with 7616-A specific en-
yme was used. Incomplete restriction enzyme digestion
ould result in overestimation of the attenuated 7616-G.
hus it is important to positively identify both nucleotide
ariants rather than simply assume that undigested DNA
epresents an alternative base at the site. The conclu-
ion that we could reach was that even though some
rabe stocks are heterogeneous at this site, others are
learly homogeneous and this property does not seem to
orrelate with vaccine performance in the field. Instead,
his mutation is likely to be only a neutral marker of a
articular virus substrain that was selected by passaging
n Vero cells. Regardless of the biological role of this
utation or absence thereof, it does not appear to be a
uitable marker for monitoring the consistency of the
enetic composition of the Urabe vaccine production.
Since there were several manufacturers that used the
rabe strain and the safety records of the products were
ifferent, we determined complete nucleotide sequences
f batches of mumps vaccine from different sources.
equencing showed that they all had characteristic pat-
erns of mutations that could be used to distinguish
etween them. Quantitative measurement (MAPREC) of
he mutations that we identified in commercial vaccine
atches produced by different manufacturers showed
hat the products can be easily distinguished from one
nother and that individual vaccine lots had very similar
utational profiles.
Comparison of nucleotide sequences of vaccine
atches with the sequences of two isolates from cases
f vaccine-associated meningitis showed that some of
he mutations detected in vaccine batches as nucleotide
eterogeneities were selected in clinical isolates and
ompletely replaced bases normally present in vaccine
irus. No consistent pattern of mutations could be iden-
ified after analysis of just two isolates. More sequence
nformation could help reveal important virulence deter-
inants. However, it is possible that there may be many
ifferent pathways leading to reversion of the attenuated
henotype, and there will be little or no consistent pat-
ern of mutations, making sequence information practi-
ally useless for predicting virus properties. Although we
ould not identify molecular markers of mumps virus
irulence and although the phenotypic manifestation of
he mutations identified in this study is unknown, the
equence information can be used for monitoring vac-
ine consistency by focusing on mutations that occur
nd are selected during vaccine production. After estab-
ishing a profile of mutations typical of the product with a
























239GENETIC VARIABILITY OF MUMPS VACCINE URABE AM9 STRAINconsistency can serve as a surrogate test for the stability
of the genetic composition of viral quasispecies regard-
less of the biological role of the mutations involved. Strict
adherence to the certified seeds and monitoring of mu-
tational profiles may ensure adequate safety of the vac-
cine.
The advent of new technological tools for direct and
accurate mutant quantification led to the possibility of
quality control of live viral vaccines. Recently MAPREC
was recommended by the World Health Organization as
a routine in vitro test for lot release of OPV (WHO, 1999).
The results presented in this paper demonstrate that a
similar approach can be used for other live viral vac-
cines.
MATERIALS AND METHODS
Vaccine bulks and clinical isolates
Bulk materials of MVL made from the Urabe AM9
strain from two manufacturers, Chiron SpA (lots PS22–
PS27) and SmithKline Beecham (SB Lot Nos. MP51,
MP52, and MP53), were provided by the manufacturers,
and two cell culture isolates from cases of postvaccina-
tion meningitis (strains 87 1004 and 87 1005) were kindly
provided by Dr. Laszlo Palkonyay (Canadian Bureau of
Biologics, Ottawa, Ontario, Canada). Biken Lot MU-9901
was kindly provided by Dr. Akihisa Takamizawa of the
Kanonji Institute Research Foundation for Microbial Dis-
eases of Osaka University Kanonji, Kagawa, Japan. All of
the samples were used directly for PCR amplification
and sequencing without further passaging in cell cul-
tures.
RNA extraction
RNA extraction was performed using the phenol/SDS
T





S4.3 4,351 GGAGTCCATT C
A4.5 4,550 TTCATGATTA C
A6.5 6,550 AGCTTGTTCT G
S6.3 6,375 TGTGGTGCGA
A8.5 8,526 CATCTGGCTC C
S8.2 8,175 CCCTTAATAA T
S9.5 9,446 GAGGAGGCAA
A10.0 10,050 CCACTGGTGA
S11.0 10,946 ATATACAGTA A
A12.0 12,012 CTGCTGCAAT G
S12.5 12,446 ACAGATTCTA A
A15.4 15,385 GACCAAGGGGmethod. SDS was added to a final concentration of 1%, aand the virus samples were extracted twice with water-
saturated phenol. The samples were precipitated with 2
vol of isopropanol overnight at 270°C.
RT reaction
Reverse transcription was performed with random
hexamer primers (New England Biolabs, NEB) in a 50-ml
olume with 600 Units of SuperScript II (Gibco BRL). The
inal RT mix was preincubated for 5 min at room temper-
ture to allow primer binding and then incubated for 45
in at 40°C. After heat inactivation of the RT (4 min at
5°C), 2–4 ml of the generated cDNA was used as a
emplate for PCR amplification.
DNA amplification by PCR
Eight different primer pairs (S1/A2.5, S2.2/A4.5, S4.3/
6.5, S6.3/A8.5, S8.2/A10, S9.5/AS12, S11/A13, and S12.5/
15.4), designated Sx.x for sense and Ax.x for antisense,
ith x.x denoting location (in kilobases) within the
umps virus genome, were used to generate overlap-
ing 1.6- to 3-kb-long PCR fragments spanning the entire
umps virus genome. Amplification was performed in a
hermocycler (Perkin–Elmer 480) with 20 pmol of each
rimer starting with initial denaturation for 1 min at 94°C,
ollowed by 35 cycles consisting of 10 s at 94°C, 40 s at
0°C, and 4 min at 68°C, and a final extension step (20
in at 72°C). Purification of the PCR fragments was
erformed with the Qiagen PCR purification kit. Primer
equences are given in Table 3.
NA sequencing
A total of 69 primers were used for PCR amplification
nd DNA sequencing of Chiron batches designated
S22, PS23, PS24, PS25, and PS27, SB batches MP51





















































240 AMEXIS, FINESCHI, AND CHUMAKOVsynthesized based on the published sequence of the
Urabe AM9 strain (Mori et al., 1997), GenBank Accession
No. AB000387. DNA sequencing was performed with an
Applied Biosystems Prism 310 Genetic Analyzer using
dRhodamine and BigDye terminators for fluorescence
detection. Then 150–250 ng of each PCR fragment and
3.2 pmol of a sequencing primer were used in 20-ml
eactions to generate 600–700 bases of readable over-
apping information from both strands. The generated
equences were edited with the Factura software pack-
ge and aligned with Auto Assembler software (both
rom Applied Biosystems). The sequences were depos-
ted with GenBank under Accession Nos. AF314558,
F314559, AF314560, AF314561, and AF314562.
utant quantification by MAPREC
The principal and general MAPREC procedures were
escribed previously (Chumakov et al., 1991; Lu et al.,
993). MAPREC is based on PCR amplification with a
utagenic primer that creates a restriction endonucle-
se site composed of both primer and template se-
uences. This site is toggled by a mutation of interest
nd can be used for detection and quantification of the
utation. Briefly, the procedure involves PCR amplifica-
ion of single-stranded DNA (produced by using a 10-fold
xcess of the sense primer), which is then radiolabeled
y second-strand DNA synthesis with 59-32P-labeled an-
tisense primer and Taq DNA polymerase. This dsDNA is
digested separately with restriction endonucleases spe-
cific for both nucleotide variants. Restriction digests are
separated by polyacrylamide gel electrophoresis, and
radioactive DNA bands are quantitated using a Storm
860 PhosphoImager (Molecular Dynamics). PCR primer
sequences used for MAPREC are listed in Table 4.
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7,616 ATGGGGGTGT CTTGCCCAAT AGTACACTCG CCTGAA
8,005 ATATTCATTC ACTCGTCCTG GTTCAGtCA GCAGTT
9,972 TGATGCGAAT CGGCCTCTAC CACAAgCA TCTAGAA
10,529 ACATTGAATT CAATGTATGG TATACCC CGCATT
Note. Lowercase letters denote nucleotides changed to create restrAnimal Research.REFERENCES
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